Preeclampsia is a severe pregnancy-related disorder, and patients usually present with high circulating inflammatory factor levels and excessive activation of the nuclear factor-κB (NF-κB) pathway. Administration of aspirin (ASP) is effective for preventing preeclampsia, and thus, we propose that ASP might affect placental function by regulating the NF-κB pathway. Systemic lipopolysaccharide (LPS) (20 μg/kg) was used to induce preeclampsia-like pregnant mouse model, and low-dose ASP (15.2 mg/kg) was administrated. Here, we report significantly increased circulatory expression levels of the proinflammatory cytokines tumor necrosis factor-alpha, interleukin-6, and soluble Fms-related tyrosine kinase-1 in LPS-treated pregnant mice, accompanied by kidney and placental dysfunction. Low-dose ASP treatment significantly reversed the preeclampsia-like phenotype, lowering hypertension, decreasing proteinuria, and ameliorating fetal growth retardation. Moreover, the excessive activation of NF-κB signaling in mice placentae induced by LPS was significantly reduced by ASP. In JEG-3 cells, LPS activated the NF-κB signaling pathway by upregulating the expression of cyclooxygenase-2 (COX-2) and related inflammatory factors, whereas the invasion ability of JEG-3 cells was weakened. However, ASP administration impeded NF-κB signaling activation, downregulated COX-2 and inflammatory factor expression, and rescued trophoblast invasion. This study provides new evidence that low-dose ASP is beneficial for preeclampsia prevention by inhibiting NF-κB and its downstream signaling pathways in trophoblast cells.
Introduction postpartum, and postpartum preeclampsia can occur in women who did not have preeclampsia during pregnancy [5] . Preeclampsia in pregnant women is often associated with a greater risk of fetal growth retardation (FGR), placental abruption, and even intrauterine fetal death [2] . Accumulating evidence indicates that the main pathological cause of preeclampsia is placental dysfunction, which is associated with endothelial injury and inadequate trophoblast invasion [6] . Although the precise mechanisms underlying preeclampsia remain unknown, the view that these complications are associated with an aberrant maternal inflammatory response is widely held [7] . Women afflicted with preeclampsia exhibit higher inflammatory states, and proinflammatory cytokines and chemokines, such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β), are elevated systemically and locally in their placentae [8, 9] . This abnormal inflammatory response leads to excessive oxidative stress and nuclear factor-κB (NF-κB) signaling activation [10, 11] .
NF-κB is a transcription factor present in various cell types that plays key roles in many physiological and pathological processes, including proliferation, differentiation, inflammation, immune response, and survival [12] . Under physiological conditions, the inactive NF-κB dimer is present, bound by the inhibitory protein kappa B (IκB) in the cytoplasm. Many stimuli, including cytokines, oxidants, pathogens, and viruses, can induce IκB phosphorylation by the IκB kinase (IKK) complex, resulting in degradation of IκB and enabling translocation of NF-κB into the nucleus [13] . This cascade initiates the transcription of genes that regulate many cell functions, including inflammation, differentiation, apoptosis, adhesion, and death [14] . NF-κB activation is reportedly significantly increased in preeclamptic placentae compared with that in normal placentae [15, 16] , which leads to high levels of TNF-α, cyclooxygenase-2 (COX-2), and thromboxane. TNF-α can also activate NF-κB, and the positive feedback loop between TNFα and the NF-κB pathway can gradually aggravate the inflammation response [10] .
Infusion of lipopolysaccharide (LPS) in pregnant rats induces excessive inflammation and leads to a preeclampsia-like phenotype; this is the classic method used to generate preeclampsia rat models [17] . Systemic LPS treatment leads to inflammatory signal transduction, inducing the release of a variety of inflammatory cytokines. As a regulator of inflammation, aspirin (ASP) given in low doses (60-150 mg/day) has been reported as a possible approach for preeclampsia and FGR prevention [18] [19] [20] . Early management with low-dose ASP in high-risk women has been shown to reduce the occurrence of earlyonset preeclampsia [18, 21] . When the administration of ASP was started before 16 weeks of gestation, the prevention effect of ASP on preeclampsia and FGR was dose dependent [22] . Moreover, administration of ASP in patients with aberrant Doppler ultrasonography of the uterine spiral artery at 12-16 weeks of gestation reduced the incidence of preeclampsia by 20% [23] . However, the prevention effect of ASP on preeclampsia was diminished when treatment started beyond 16 weeks [22, 24] . These findings illustrate the importance of early preeclampsia intervention with ASP to improve placental function in high-risk patients. The anti-inflammatory effect of ASP is due to its ability to suppress the production of NF-κB-regulated genes, including COX and TNF-α [25, 26] . Because preeclampsia is usually associated with a severe inflammatory response, application of low-dose ASP to modulate the NF-κB signaling pathway might be helpful in alleviating excessive inflammation in these patients.
Based on these data, we speculated that LPS could upregulate inflammatory responses in pregnant mice, potentially targeting NF-κB signaling and leading to the occurrence of preeclampsia.
Low-dose ASP might inhibit the inflammatory response and NF-κB signaling activation and alleviate the symptoms of preeclampsia. To investigate these assumptions, the preeclampsia-related phenotype and NF-κB signaling activation in LPS-treated mice were examined, and the roles of low-dose ASP in preeclampsia were evaluated. The present study demonstrates that application of low-dose ASP improves the preeclampsia-like phenotype in an LPS-induced mouse model. Furthermore, the treatment of JEG-3 cells with ASP modulated LPS-induced NF-κB activation and affected cell function in vitro.
Materials and methods

Animals and experimental protocols
Experimental permission for this study was granted by the Animal Ethics Committee of Peking University First Hospital. Female CD1 Institute of Cancer Research mice (8 weeks old) were maintained in a specific pathogen-free environment with a fixed 12-h/12-h light/dark cycle, and food and water were available ad libitum. Mating was performed overnight, and noon on the day of plug detection was considered embryonic day 0.5 (E0.5).
Pregnant mice were randomly divided into four groups: control group (CTRL, N = 18), LPS-treated group (N = 18), ASP-treated group (N = 18), and LPS + ASP co-treatment group (N = 18). Mice in the CTRL group were treated with saline according to the dissolved volume of LPS or ASP. For the LPS-treated group, 20 μg/kg LPS (Sigma Aldrich, USA) was intraperitoneally injected daily from E7.5 to E17.5. ASP (Sigma Aldrich) at a dose of 15.2 mg/kg dissolved in saline was intragastrically infused 2 h after LPS administration daily from E7.5 to E17.5. On E18.5, the pregnant mice were anesthetized with 10% chloral hydrate (3 ml/kg, intraperitoneal injection). The fetuses and placentae were isolated by mechanical dissection of the conceptus, and their wet weights were recorded immediately after collection.
Blood collection
The mice were made comfortable in a restrainer wherein the temperature was maintained at approximately 24
• C to 27
• C. They were placed in an appropriate restraint device with their tail extended, and a small nick over the lateral tail vein was made using a sterile scalpel blade. A collection tube was used to collect the blood. Once a sufficient amount of blood was collected, the nick was pressed with clean gauze to stop the flow of blood.
Blood pressure and urinary protein levels
The systolic blood pressure (SBP), mean blood pressure, and diastolic blood pressure (8:00 a.m.-11:00 a.m.) of each mouse were monitored daily using a tail-cuff plethysmograph (Softron, Japan). All the female mice were acclimatized to the blood pressure procedures prior to pregnancy. Urine from each mouse was collected on E13.5 and E18.5 with dams housed individually in metabolic cages with no food. The urinary albumin levels were measured by an Albumin Assay Kit (Bethyl Laboratories, USA), and urinary creatinine concentrations were determined using a Creatinine Assay Kit (Cayman Chemical, USA). The ratio of urinary albumin to creatinine was calculated as the proteinuria index as previously described [27] .
Immunostaining and periodic acid-Schiff staining
Placental and kidney (E18.5) tissues were fixed in 4% paraformaldehyde (Sigma Aldrich) overnight at 4
• C and embedded in paraffin For the immunohistochemical analysis of trophoblast invasion and vascular branches in the mice placentae, tissue samples from at least six mice per group and at least three placentae per mouse were used. The position of the yolk sac was used as a guide to locate the central position of the placenta. At least four to six sections from the center of the placenta were used for immunohistochemical analysis. Slides stained for laminin were further examined by Photoshop software to quantify the fetal blood vessel (FBV) and maternal blood sinusoid (MBS) areas.
Periodic acid-Schiff (PAS) staining was utilized for the observation of glomerular structures. The extent of renal injury was evaluated by quantifying the glomeruli showing narrowed Bowman's spaces and occlusion of capillary loop spaces. To examine these features quantitatively, glomeruli in five fields of randomized and blinded slides (×10 magnification) were counted. The glomeruli in each field were given a score based on the amount of capillary space evident within the Bowman's capsule as described previously [28] . The highest score of 5 was awarded to glomeruli with a normal amount of capillary space within the Bowman's capsule. A score of 1 was assigned to glomeruli that showed complete loss of capillary space, and an intermediate score of 3 was assigned to glomeruli that displayed reduced, but not completely erased, capillary spaces. The scores for each field were divided by the number of glomeruli to obtain an average score per glomerulus for each field.
ELISAs
The plasma concentrations of TNF-α, IL-6, and soluble Fms-related tyrosine kinase-1 (sFlt-1) in the mice were measured using the Mouse TNF-α Quantikine ELISA Kit (R&D Systems, Australia), the Mouse IL-6 Quantikine ELISA Kit (R&D Systems, Australia), and the Mouse VEGF R1/Flt-1 Quantikine ELISA Kit (R&D Systems, Australia), respectively, according to the manufacturer's instructions. The concentrations were determined according to the absorbances of the samples and standards at a wavelength of 450 nm obtained using a microplate reader (BioTek, USA).
Cell culture and treatment
JEG-3 choriocarcinoma cells were purchased from American Type Culture Collection (ATCC) and cultured in Dulbecco Modified Eagle medium (DMEM) (Invitrogen, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco, USA). The cells were maintained in a humidified incubator at 37
• C with 5% CO 2 and 95% air. Before being treated with LPS and ASP (Sigma Aldrich, USA), the cells were starved for 24 h in medium containing 0.5% FBS. For the treatment experiments, cells were treated with LPS (10 μg/ml) alone for 24 h or ASP (5 × 10 −4 M) 12 h after LPS treatment. The treated cells were collected, and RNA and protein were extracted immediately.
Transient transfection experiments were carried out using Lipofectamine 2000 according to the manufacturer's instructions (Invitrogen, USA). The siRNA duplexes were products from GenePharma (Shanghai, China).
RNA preparation and quantitative real-time PCR
Total RNA was extracted with TRIzol reagent (Invitrogen, USA) and reverse transcribed into cDNA using the oligo deoxy thymidine primer (Amersham Biosciences, USA). Real-time PCR was carried out using the LightCycler480 sequence detection system (Roche, CH). The primer sequences were as follows: human TNF-α, 5 -CACCACTTCGAAACCTGGGA-3 (forward) and 5 -AGGAAGGCCTAAGGTCCACT-3 (reverse); human IL-6, 5 -CTCAATATTAGAGTCTCAACCCCCA-3 (forward), and 5 -GTGGGGCGGCTACATCTTT-3 (reverse); human sFlt-1, 5 -TTTGCATAGCTTCCAATAAAGTTG-3 (forward) and 5 -CATGACAGTCTAAAGTGGTGGAAC-3 (reverse); human IL-1β, 5 -AAGTACCTGAGCTCGCCAGT-3 (forward) and 5 -TGTCCATGGCCACAACAACT-3 (reverse); human glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 5 -GAAGGTGAAGGTCGGAGTC-3 (forward) and 5 -GAAGATGGTGATGGGATTTC-3 (reverse); mouse TNF-α, 5 -AGGCACTCCCCCAAAAGATG-3 (forward) and 5 -TGAGGGTCTGGGCCATAGAA-3 (reverse); mouse IL-6, 5 -CTCATTCTGCTCTGGAGCCC-3 (forward) and 5 -GACAGGTCTGTTGGGAGTGG-3 (reverse); mouse IL-1β, 5 -TGCCACCTTTTGACAGTGATG-3 (forward) and 5 -GCCTGAAGCTCTTGTTGATGTG-3 (reverse); mouse sFlt-1, 5 -CCACCTCTCTATCCGCTGG-3 (forward) and 5 -ACCAATGTGCTAACCGTCTTATT-3 (reverse); and mouse GAPDH, 5 -CTCTTCCACCTTCGATGCCG-3 (forward) and 5 -TTATGGGGGTCTGGGATGGA-3 (reverse). All PCRs were performed in triplicate, and statistical analysis of the results was performed using the Ct value (Ct target gene-Ct GAPDH). The CT method of relative quantification was used to determine expression fold changes [29] .
Western blotting analysis
Total protein was extracted using RIPA lysis buffer, and 40 μg of protein was subjected to 10% SDS-PAGE and subsequently electrotransferred to a nitrocellulose membrane (Amersham Pharmacia Biotech, UK). The antibodies included IKKβ (1:1000), p-IKKβ (1:1000), IκBα (1:1000), p-IκBα (1:800), NF-κB (1:1000), p-NF-κB (1:1000, all from Cell Signaling Technology, USA), COX-2 (1:800, Abcam, UK), β-actin (1:5000, Ambion, USA), and horseradish peroxidase-conjugated secondary antibody (Promega, USA). Final visualization was achieved using an enhanced chemiluminescence western blotting analysis system (Pierce, USA). The relative densities of the detected proteins were determined by normalization to that of β-actin, IKKβ, IκBα, or NF-κB in the same blot.
Transwell invasion assay
In vitro cell invasion was assayed by determining the ability of cells to invade a synthetic basement membrane, growth factor-reduced Matrigel matrix (BD Biosciences, USA). JEG-3 trophoblast cells were treated with LPS (10 μg/ml) for 24 h or ASP (5 × 10 −4 M) after the first 12 h of LPS treatment. The cells were then used for the invasion assays. Briefly, 24-well fitted transwell inserts with membranes (8-μm pore size) (Corning, USA) were coated with growth factor-reduced Matrigel at 200 μg/ml and placed in a 24-well plate. JEG-3 cells at 6 × 10 5 /ml were seeded in each insert with DMEM containing 0.1% FBS. After incubating for 24 h, the cells were fixed in 0.25% glutaraldehyde and stained with hematoxylin. Noninvaded cells on the upper surface of the membrane were removed, and the number of stained cells was counted using a light microscope with a twofold objective. All experiments were performed in triplicate, and the invasion index was expressed as the percentage of invaded cells compared with the corresponding control.
Statistical analysis
Data are presented as the mean ± SEM. All data were subjected to statistical analysis using two-way analysis of variance and Student two-tailed t tests to determine significance between groups. Pvalues less than 0.05 were considered significant. All statistical analyses were carried out using GraphPad Prism 5 software (GraphPad Software, USA).
Results
ASP ameliorated hypertension, proteinuria, and FGR in LPS-treated mice
To assess whether LPS administration induced the preeclampsia-like phenotype, we assessed the blood pressures, urine protein levels, and fetal-placental development of the mice. Compared with the CTRL group, LPS-treated mice exhibited increased SBP from E8.5 to E18.5, which resembled gestational hypertension in early-onset preeclamptic women ( Figure 1A ). The level of urinary protein was elevated in the LPS-treated group at E18.5, which was approximately twofold higher than that of the CTRL group ( Figure 1B) . Hence, an LPS-induced preeclampsia-like mouse model was established. Using this model, ASP was administered to mimic the preventive effect in clinical study. By receiving ASP daily, the SBP was reduced to normal levels in the LPS + ASP group compared with those in the LPS group from E10.5 to E18.5. No significant changes in blood pressure in the ASPtreated group were observed ( Figure 1A ). ASP could ameliorate the proteinuria induced by LPS, and no significant changes in urinary protein levels were observed in the ASP-treated group ( Figure 1B) . Furthermore, the fetal and placental weights in each group were analyzed ( Figure 1C and D) . Compared with the fetal weight in the CTRL group, that in the LPS-treated group was lower by approximately 15%. Placental weight was significantly reduced by approximately 29% in the LPS group compared with that in the CTRL group. Thus far, obvious FGR was observed in mice treated with LPS. However, ASP administration significantly ameliorated FGR. Compared with the fetal weight in the LPS-treated group, that in the LPS + ASP group was higher by approximately 9%, and the placental weight was significantly increased by approximately 23% in the LPS + ASP group. ASP alone had no effect on the fetal and placental weights compared with those of the CTRL group.
These results indicated that ASP ameliorated the preeclampsialike phenotype in an LPS-induced mouse model, as indicated by the reduction in blood pressure and proteinuria. Moreover, ASP recovered fetal and maternal weight.
ASP prevented LPS-induced mice from kidney and placental injury
Preeclampsia is generally associated with impaired renal function and characteristic alterations in renal histology. Immunohistochemical analysis of pathological kidney changes on E18.5 showed numerous fibrin depositions in the vascular endothelia of kidneys from LPS-treated mice compared with those of the CTRL group (Figure 2A, a and b) . Statistical analysis of the mean fibrin OD showed significantly increased OD values per area in the LPS-treated group compared with those of the CTRL group. ASP could reduce fibrin deposition in the kidneys of LPS-treated mice (Figure 2A, c) by approximately 60%. PAS staining showed that swollen glomeruli with narrowed capillaries and Bowman's spaces in the kidney, which were pathognomonic for renal disease that often occurs in women with preeclampsia [30] , in the LPS-treated group were significantly more extensive than those of the CTRL group (Figure 2A, e and f) . Scores in the LPS group, based on the amount of capillary space within the Bowman's capsule, were significantly lower than those in the CTRL group. ASP (LPS + ASP) could attenuate the renal damage of reduced glomeruli and narrowed capillaries and Bowman's spaces, as higher scores were observed in this group compared with those of the LPS group (Figure 2A, g ). ASP alone had no effect on fibrin deposition and kidney damage (Figure 2A, d and h) .
Next, placental structures on E18.5 were analyzed by immunohistochemistry. Placentae are composed of three parts: the deciduae tissues, the junction zone, and the labyrinth [31, 32] . Laminin staining displayed fetal vascular blood in the labyrinth region of the placenta ( Figure 2B ). Furthermore, the FBV and MBS in the labyrinth region were marked by a pseudo color, and the total FBV and MBS areas were statistically analyzed. The total FBV area was decreased in the LPS-treated group compared with that of the CTRL group, while the administration of ASP could rescue this reduction induced by LPS ( Figure 2B ). Trophoblast invasion plays an important role in spiral artery remodeling, and insufficient spiral artery remodeling serves as the main factor underlying preeclampsia [31, 33] . The pan-trophoblast marker cytokeratin 8 (CK8) was used to label trophoblast giant cells (TGCs) invading deciduae tissues. The number of CK8-positive TGCs that invaded the decidua (from the baseline between the decidua and spongiotrophoblast cells, yellow line) was counted. The number of TGCs in the decidua was significantly decreased by approximately 50% in the LPS group compared with that of the CTRL. However, ASP and LPS co-treatment promoted the invasion of TGCs into the decidua, as the number of decidual CK8-positive cells in this group was increased by 64% compared with that of the LPS group ( Figure 2C ). ASP alone had no effect on blood vessel development or trophoblast invasion.
ASP alleviated the upregulation of inflammation factors in LPS-induced mice
LPS could reportedly induce rats to present with preeclampsia-like syndrome by stimulating the release of inflammation factors [17] . Hence, the inflammation factors TNF-α, IL-6, and sFlt-1 in peripheral blood of the mice were detected ( Figure 3A) . On E7.5, the plasma TNF-α levels in the LPS-treated group were approximately 80-fold higher than those of the CTRL group 4 h after LPS treatment, which was significant. The level of IL-6 in the LPS-treated group was significantly higher than that in the CTRL group (50-fold). Plasma levels of sFlt-1, the soluble form of the vascular endothelial growth factor (VEGF) receptor, are significantly elevated in preeclamptic women, and sFlt-1 is believed to contribute to the disease pathology by interfering with VEGF signaling [34, 35] . Our results indicated that the sFlt-1 concentration in LPS-treated mice was significantly higher (3.2-fold) than that in mice of the CTRL group on E18.5 ( Figure 3A) . The placental expression levels of TNF-α, IL-6, sFlt-1, and IL-1β in each group were also detected by qRT-PCR on E18.5. LPS could significantly promote the expression of these factors, as the TNF-α (2.3-fold), IL-6 (1.4-fold), sFlt-1 (5.7-fold), and IL-1β (1.6-fold) levels in this group were increased compared with those of the CTRL group ( Figure 3B ). ASP is an effective anti-inflammatory drug in clinical research [20] , and results have shown that ASP can reduce TNF-α, IL-6, and sFlt-1 by 30%, 42%, and 52%, respectively, in peripheral blood. The placental expression of TNF-α, IL-6, sFlt-1, and IL-1β decreased by 45%, 50%, 40%, and 30%, respectively ( Figure 3B ). ASP treatment alone had no effect on the production of inflammatory factors ( Figure 3A) . Thus, ASP could reduce the production of inflammatory factors promoted by LPS in peripheral blood and placentae.
ASP rescued the activation of NF-κB signaling in LPS-induced mice
The activation status of NF-κB signaling in placentae of LPS-induced mice was examined by western blotting for phosphorylated IKKβ (p-IKKβ), phosphorylated IκBα (p-IκBα), and phosphorylated NF-κB (p-NF-κB). The levels of p-IKKβ, p-IκBα, and p-NF-κB were significantly elevated in the LPS-treated mice compared with those in the CTRL group, although there were no significant differences in the total IKKβ, IκBα, and NF-κB expression levels in the two groups. Statistical analysis showed that the placental levels of p-IKKβ/IKKβ, p-IκBα/IκBα, and p-NF-κB/NF-κB in LPS-treated mice were 9.1-, 1.7-, and 1.6-fold higher than those of the CTRL group. Moreover, the expression of COX-2 was increased 2.6-fold in the LPSinduced group compared with that in the CTRL group. However, the administration of ASP could rescue the activation of NF-κB signaling in LPS-induced mice, as the ratios of p-IKKβ/IKKβ, p-IκBα/IκBα, and p-NF-κB/NF-κB were decreased by 46%, 31%, and 29%, respectively, compared with those in the LPS-treated group. Furthermore, the level of COX-2 in the LSP + ASP group was reduced by 36% compared with that in the LPS-treated group ( Figure 4A and B) . This result indicated that ASP could attenuate the overactivation of NF-κB signaling induced by LPS in mice placentae. and NF-κB in the LPS-treated group were significantly increased by 3.5-, 8.2-, and 3.9-fold compared with those of the CTRL group. In the presence of ASP, the phosphorylation levels of IKKβ, IκBα, and NF-κB were reduced by 48%, 55%, and 68%, respectively. ASP treatment alone did not affect the phosphorylation of IKKβ, IκBα, and NF-κB. Meanwhile, the downstream protein COX-2 was also upregulated 4.2-fold in the LPS-treated group compared with that in the CTRL group. However, in the presence of ASP, the level of COX-2 was reduced by 56%. Thus, ASP treatment alone does not affect the level of COX-2 ( Figure 5A ). To further confirm the regulation of ASP on NF-κB signaling, we transfected JEG-3 cells with IKKβ-specific siRNA (100 nM) for 24 h to knock down its expression. JEG-3 cells were then treated with LPS (10 μg/ml) for 24 h in the presence or absence of ASP (5 × 10 −4 M) during the final 12 h. Based on these procedures, COX-2 expression was detected, revealing that IKKβ knockdown could largely block LPS-induced COX-2 upregulation, whereas co-treatment with ASP had no effect on COX-2 expression ( Figure 5B ). These results further explained that the regulatory effect of ASP on LPS-induced JEG-3 cells was NF-κB-dependent.
At the same time, we examined the expression of inflammatory factors in each group. Compared with those of the CTRL group, LPS treatment significantly upregulated the levels of TNF-α, IL-6, sFlt-1, and IL-1β at the mRNA level by 2.3-, 2.5-, 3.2-, and 9.1-fold, respectively. The upregulation of TNF-α, IL-6, sFlt-1, and IL-1β induced by LPS could be reduced by 56%, 37%, 35%, and 73%, respectively, in the presence of ASP. However, when IKKβ expression was knocked down, the LPS-induced upregulation of TNF-α, IL-6, sFlt-1, and IL-1β was largely blocked. Neither co-treatment with ASP nor ASP alone affected the expression of these factors ( Figure 5C ).
The transwell invasion assay showed that the invasive ability of JEG-3 cells was reduced to 30% of that of the control group when LPS treatment was applied for 24 h. However, in the presence of ASP, the tremendous invasion-inhibiting effect of LPS could be largely blocked, as the invasion index in the LPS + ASP group was 2.1-fold higher than that of the LPS-treated group. ASP treatment alone did not affect the level of cell invasion ( Figure 5D ). These results indicated that ASP could regulate the invasion of trophoblast cells dependent upon the NF-κB signaling pathway.
Discussion
In this study, we demonstrated that ASP ameliorated the preeclampsia-like phenotype induced by LPS in a mouse model; ASP attenuated the associated high blood pressure and proteinuria. The placental dysplasia and kidney injury induced by LPS were also improved by ASP administration. Moreover, ASP rescued the overactivation of NF-κB signaling and upregulation of downstream inflammatory factors and COX-2 in mouse placentae induced by LPS. These findings indicate that ASP has an anti-inflammatory effect in a preeclampsia-like mouse model. Abnormally activated inflammation is responsible for preeclampsia occurrence. In women with preeclampsia, circulating TNF-α levels are reportedly increased [36] , but the exact cause of the increase in inflammatory factor production and its pathogenic role are unknown. LPS injection is regarded as the traditional method of generating a preeclampsia-like rat model [17] . The LPS-treated mouse model of preeclampsia described herein provides strong experimental support that preeclampsia is an inflammatory disease. Systemic LPS administration leads to the release of inflammatory factors in early pregnancy. Given that placentation occurs after implantation (E4.5) between E4.5 and E10.5 in mice [31] , in this study, LPS was administered to pregnant mice on E7.5, and shallow trophoblast cell invasion and inadequate angiogenesis were successfully mimicked.
Placental perfusion is dependent upon sufficient remodeling of uterine spiral arteries. Therefore, inadequate spiral artery remodeling is thought to explain the reduced placental perfusion associated with preeclampsia. Despite the close relationship between aberrant maternal inflammation and preeclampsia, we still do not know whether the inflammation response is the cause of spiral artery remodeling failure. Using the LPS-induced mouse model, we describe a mechanism by which aberrant maternal inflammation results in abnormal spiral artery remodeling. Our study also reveals that inflammation-induced deficiency in vascular remodeling is associated with the features of preeclampsia.
NF-κB signaling is significantly activated in women with preeclampsia [11] . In the LPS-induced mouse model, placentae presented high NF-κB signaling activation and COX-2 upregulation. NF-κB pathway activation in the placenta subsequently evokes the expression of downstream inflammatory factors, which served as intermediaries in the cascade reaction of preeclampsia. Increased placental secretion of proinflammatory factors into the circulation is believed to be responsible for systemic endothelial dysfunction, hypertension, and multiorgan functional damage [37, 38] . During placental development, these excessive inflammatory factor levels lead to abnormal trophoblast invasion and spiral artery remodeling [39] , which induces placental dysfunction and the onset of preeclampsia. Importantly, elevated sFlt-1 levels are known to contribute to the pathophysiology of preeclampsia, including deficient placentation, hypertension, and kidney damage [40] . Many studies have shown that circulating sFlt-1 levels are significantly upregulated in preeclamptic women compared with those in women experiencing normal pregnancies [35, 41, 42] . Notably, sFlt-1 administration in pregnant rats leads to proteinuria and hypertension, which represent the critical phenotype of preeclampsia [30] . Here, we showed that LPS injection in pregnant mice induced TNF-α, IL-6, and sFlt-1 production. Our study provides evidence that LPS administration induces a preeclampsia-like phenotype in pregnant mice. Several systematic reviews have indicated that ASP can prevent the occurrence of early-onset preeclampsia in high-risk women when initiated before 16 weeks of gestation [22, 43, 44] . ASP is known to inhibit COX and reduce the level of platelet aggregators and vasodilatory prostacyclin. A previous study showed an effect of ASP on vascularization that inhibited the COX-1 pathway in preeclampsia through reduction of the ratio of thromboxane A 2 and prostacyclin [45] . However, the COX-2 pathway, which is activated by inflammation, has been increasingly associated with the etiology of preeclampsia [46] . Thus, the effect of ASP on the COX-2 pathway in preeclampsia prevention needs further exploration. Our results indicate that ASP inhibits COX-2 expression under high inflammation conditions, but elucidating the involved mechanisms still requires further research.
In our mouse model, ASP treatment was started at E7.5, and the dose used was equivalent to 100 mg/day in pregnant women with an average weight of 60 kg. Given that the proportion of weight gain in mice during pregnancy is much more than that in humans, the dose of ASP used was 15.2 mg/kg and was increased with the weight gain in mice. LPS-induced mice were in a state of systemic inflammation, which is a high-risk state for preeclampsia. Thus, ASP was administered in early pregnancy for intervention treatment. The results confirmed that ASP can rescue the high inflammatory factor and sFlt-1 levels both in the circulation and placenta and block the NF-κB overactivation and COX-2 upregulation in mouse placentae induced by LPS. Thus, ASP is crucial in regulation of NF-κB signaling during the preeclampsia process.
Furthermore, we evaluated the in vitro regulatory effect of ASP on LPS-treated JEG-3 cells. A previous study showed an inhibition effect of ASP on lipid peroxides, thromboxane, and prostacyclin in preeclamptic placenta, and the effects were dose dependent (from 10 −6 M to 5 × 10 −4 M). The research indicated that 5 × l0
M ASP could approximate the concentration of salicylate in the umbilical circulation when maternal intake was 100 mg ASP [47] .
Other in vitro studies showed that the appropriate dosage of ASP varies from 5 × 10 −5 M to 3 × 10 −3 M [48, 49] . An in vivo study indicated that oral medication and intravenous injection of 50 mg ASP generated a maximum plasma concentration of 1.3 and 6 μg/ml of ASP, respectively, in normal individuals [50] . In clinical usage, doses of ASP between 50 and 160 mg are typically administered, and the recommended dosage used for preeclampsia prevention is 60-150 mg daily [20] . Indeed, many differences might modulate the effects of ASP when administered orally compared with those induced after in vitro cell culture administration. These differences include in vivo deacetylation of ASP in the liver, which is different from that in cultured cells, and in vivo elimination by the kidneys that cannot be mimicked in vitro. Nonetheless, treatment of JEG-3 cells with 5 × 10 −4 M ASP in this study showed that the LPS-induced activation of NF-κB and upregulation of TNF-α, IL-6, IL-1β, sFlt-1, and COX-2 can be significantly inhibited. Moreover, ASP blocked the invasion inhibition effect of LPS on JEG-3 cells. All the data indicate that ASP treatment alone does not affect the physiological state of mice or the function of trophoblast cells.
The anti-inflammatory activity of ASP in pregnant LPS-induced mice suggests that this drug might be helpful in moderating inflammatory responses developed during preeclampsia. Furthermore, ASP might play modulatory roles in the inflammatory activity of trophoblast cells. This report is the first to combine an in vivo animal model and in vitro trophoblast cell experiments to verify the effect of ASP on the regulation of an inflammation-related signaling pathway during preeclampsia. Therefore, administration of ASP as an anti-inflammatory drug to women with this syndrome might be a prevention and therapeutic option.
In conclusion, ASP exerted inhibitory effects on LPS-induced NF-κB activation and on the transcription factors responsible for inducing TNF-α, IL-6, IL-1β, sFlt-1, and COX-2 production. Considering the well-known mechanism and safety of ASP at the cellular level and recent clinical practices, additional studies are recommended in other types of models to further verify the effectiveness of ASP as a useful drug for preventing the inflammatory manifestations associated with preeclampsia.
